AbbVie secures exclusivity on hepatitis C drug with cheaper price

December 22, 2014 6:41 PM

16 1

AbbVie has substantially cut the price of its newly approved hepatitis C drug to win an exclusive deal with Express Scripts, the nation's largest manager of prescription drug benefits, the companies said Monday.

Starting Jan. 1, Express Scripts will stop offering the leading versions of the drug made by Gilead Sciences and Johnson & Johnson, which start at $84,000 for some 12-week treatments.

Read more

To category page